Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Prevalence of SARS-CoV-2 antibodies in Germany

Seroprevalence studies have proved their worth in estimating the size and directionality of an outbreak of infectious disease, especially the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19). A new study posted to the medRxiv* preprint server describes the prevalence of SARS-CoV-2 antibodies in five representative regions of Germany.

10 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

Targeted methods to control spread of SARS-CoV-2 without resorting to lockdowns

Researchers at the Center for the Ecology of Infectious Diseases and the College of Public Health at the University of Georgia revealed alternative ways to control the pandemic spread without resorting to these measures.

9 May 2021

SARS-CoV-2 main protease conformations are temperature-dependent

New research led by Daniel A Keedy of City University of New York, USA, shows the structure of the main protease (Mpro) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative pathogen of coronavirus disease 2019 (COVID-19) – reacts to being heated and cooled. The temperature-dependent conformations could act as potential therapeutic targets to neutralize the virus.

9 May 2021

Is COVID-19 a new disease?

In a review recently published in The Lancet Respiratory Medicine journal by Osuchowski et al. (May 6th, 2021) the currently known pathophysiology of COVID-19 is laid out to describe the mechanistic features that make COVID-19 distinct from many conditions previously thought to be similar.

9 May 2021

Researchers identify anti-inflammatory prodrug Minnelide with potential against SARS-CoV-2

Using a transgenic mouse model of COVID-19, they have observed that treatment with Minnelide reduces viral load and inflammation in the lungs and improves survival. The study is currently available on the bioRxiv* preprint server.

9 May 2021

Increased heart rate as a physiological response to SARS-CoV-2 mRNA vaccine

Although widely publicized, evidence for physiological responses to the vaccines is currently scarce in published literature. Giogiro Quer and Matteo Gadaleta of the Scripps Research Translational Institute in California, USA, led an investigation to obtain tracking data for physiological responses to vaccine programs.

8 May 2021

Unique infectious profile explains why it is so hard to treat COVID-19

A comprehensive review into what we know about COVID-19 and the way it functions suggests the virus has a unique infectious profile, which explains why it can be so hard to treat and why some people experience so-called "long-COVID", struggling with significant health issues months after infection.

7 May 2021

Pfizer-BioNTech mRNA vaccine reduces both symptomatic and asymptomatic COVID-19 infection in case study

Follow-up of vaccinated and unvaccinated individuals at St. Jude Children’s Research Hospital revealed asymptomatic infection reduced by 90% and symptomatic infections reduced by up to 96% in vaccinated people compared to those not vaccinated.

7 May 2021

How did SARS-CoV-2 first evolve in humans?

In a perspective article recently published in the journal Science, Hyeryun Choe and Michael Farzan from the Scripps Research Institute, USA, have described the early-stage evolution of SARS-CoV-2 in humans. They have provided a detailed overview of how early mutations in SARS-CoV-2 spike protein facilitate its adaptation in human systems.

7 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

The ancestor of SARS-CoV-2’s Wuhan strain was circulating in late October 2019

The SARS-CoV-2 was first reported in a case from Wuhan, China, in December 2021, and subsequently became the cause of the COVID-19 pandemic that is ravaging the world today. A new study in the journal Molecular Biology and Evolution tracks its variants all over the world since the onset of the pandemic.

7 May 2021

Are infants at greater risk of COVID-19 than children?

The widely circulating SARS-CoV-2 has caused the devastating COVID-19 pandemic. The impact of this infection varies significantly with age, sparing young children for the most part, though not completely. However, a new study, released as a preprint on the medRxiv* server, shows that infants are not as resistant to the virus as children are. The researchers trace this to the expression of ACE2 to varying extents in different groups.

7 May 2021

Could antiviral surface designs help reduce SARS-CoV-2’s spread?

In an effort to improve surface decontamination methods, researchers from the Indian Institute of Technology (IIT), Bombay, looked at fabricating surfaces with virucidal properties. More specifically, these scientists investigated surface properties that could prevent the survival of viruses on these surfaces, particularly SARS-CoV-2.

7 May 2021

Human organoids useful for modeling COVID-19 variants of concern, finds study

A new study published on the bioRxiv* preprint server found that using human organoids could help with better characterizing the phenotype of several viral variants, including B.1.1.7. Their findings show the ribonucleic acid (RNA) shedding of the SARS-CoV-2 variant correlated with viral fitness and infectiousness.

7 May 2021

Highly efficient immune response in asymptomatic SARS-CoV-2 patients

Researchers in Singapore have investigated the role of SARS-CoV-2-specific antibodies and T-cells in asymptomatic individuals suffering from COVID-19. They found that, contrary to some initial hypotheses, asymptomatic individuals mount an adaptive immune response on par with symptomatic individuals, demonstrating that T cell response does not appear to be correlated with symptom severity.

7 May 2021

SARS-CoV-2 infection prolongs viral shedding and lymphocyte loss in patients with cancer

Patients with cancer have a more challenging time with infections while undergoing treatment — placing them as high-risk for severe COVID-19 illness and death. However, how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts with cancer therapies remains poorly understood.

7 May 2021

Cryptic pocket on the surface of SARS-CoV-2 may be a promising treatment target

In a new study currently available on the bioRxiv* preprint server, a multinational group of researchers modeled an entire membrane-embedded spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlighted the potential of a specific mapping approach for unveiling cryptic, potentially druggable pockets on the viral surface.

7 May 2021

Study reports vitamin C inhibits SARS-CoV-2 virus main protease

Based on structural analysis, researchers found that vitamin C binds to 3CLpro, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease essential in viral replication. In vitro cell inhibition studies also showed vitamin C could inhibit 3CLpro, indicating a possible new antiviral treatment method.

6 May 2021

Israeli study shows real-world efficacy of Pfizer-BioNTech’s COVID-19 vaccine

Researchers have conducted an analysis of nationwide surveillance data from Israel demonstrating the real-world effectiveness of Pfizer-BioNTech’s BNT162b2 vaccine at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

6 May 2021